The F2RL1 antibody targets the protein encoded by the F2RL1 gene, also known as protease-activated receptor 2 (PAR2), a G protein-coupled receptor (GPCR) activated by proteolytic cleavage. PAR2 plays a critical role in inflammatory responses, pain signaling, and cancer progression. It is expressed in various tissues, including the vascular endothelium, immune cells, and epithelial cells. Activation of PAR2 by serine proteases (e.g., trypsin, mast cell tryptase) or synthetic ligands triggers intracellular signaling pathways, influencing processes like cytokine release, cell proliferation, and vascular permeability. Dysregulation of PAR2 is linked to chronic inflammation, neurodegenerative diseases, and tumor metastasis.
F2RL1 antibodies are essential tools for studying PAR2 expression, localization, and function in physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and flow cytometry to assess receptor levels in disease models or clinical samples. In research, these antibodies help elucidate PAR2's role in tumor microenvironments, neuroinflammatory disorders, and metabolic syndromes. Additionally, F2RL1 antibodies aid in evaluating therapeutic interventions targeting PAR2. such as inhibitors designed to block its pro-inflammatory or pro-tumorigenic effects. Their specificity and reliability make them valuable for both basic research and drug development.